lajollapharmaceutical.com

La Jolla Pharmaceutical Company |

We are dedicated to the discovery, development, and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. La Jolla is developing LJPC-401 for the potential treatment of iron overload, which occurs as a result of hereditary hemochromatosis (HH), a genetic deficiency of hepcidin, or as a result of frequent blood transfusions required to treat diseases such as beta thalassemia and sickle cell disease (SCD).

http://www.lajollapharmaceutical.com/

OVERVIEW OF lajollapharmaceutical.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

20

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR LAJOLLAPHARMACEUTICAL.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

August

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.0 out of 5 with 16 reviews

5 star

9

4 star

2

3 star

3

2 star

0

1 star

2

Hey there! Start your review of lajollapharmaceutical.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

0.7 seconds

FAVICON PREVIEW

16x16
32x32
64x64
128x128
160x160
192x192
256x256

CONTACTS AT LAJOLLAPHARMACEUTICAL.COM

Domains By Proxy, LLC

Registration Private

Domain●●●●●●xy.com

14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309

Sco●●●ale , Arizona, 85260

UNITED STATES

1480●●●●2599

1480●●●●2598

LA●●●●●●●●●●●●●●●●●●●●●●●@domainsbyproxy.com

View this contact

Domains By Proxy, LLC

Registration Private

Domain●●●●●●xy.com

14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309

Sco●●●ale , Arizona, 85260

UNITED STATES

1480●●●●2599

1480●●●●2598

LA●●●●●●●●●●●●●●●●●●●●●●●@domainsbyproxy.com

View this contact

Domains By Proxy, LLC

Registration Private

Domain●●●●●●xy.com

14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309

Sco●●●ale , Arizona, 85260

UNITED STATES

1480●●●●2599

1480●●●●2598

LA●●●●●●●●●●●●●●●●●●●●●●●@domainsbyproxy.com

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: 2014 April 22
UPDATED: 2014 April 22
EXPIRATION: EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

DOMAIN AGE

10

YEARS
1

MONTHS
15

DAYS

NAME SERVERS

1: ns23.domaincontrol.com
2: ns24.domaincontrol.com

REGISTRAR

GODADDY.COM, LLC

WHOIS : whois.godaddy.com

REFERRED : http://registrar.godaddy.com

CONTENT

PAGES IN
THIS WEBSITE

20

SSL

EXTERNAL LINKS

8

SITE IP

166.62.112.199

LOAD TIME

0.678 sec

SCORE

6.2

PAGE TITLE

La Jolla Pharmaceutical Company | | lajollapharmaceutical.com Reviews

<META> DESCRIPTION

We are dedicated to the discovery, development, and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. La Jolla is developing LJPC-401 for the potential treatment of iron overload, which occurs as a result of hereditary hemochromatosis (HH), a genetic deficiency of hepcidin, or as a result of frequent blood transfusions required to treat diseases such as beta thalassemia and sickle cell disease (SCD).

<META> KEYWORDS

1 about us

2 board of directors

3 management

4 careers

5 research pipeline

6 giapreza

7 grants

8 investor relations

9 corporate update

10 corporate presentation

CONTENT

Page content here

KEYWORDS ON PAGE

about us,board of directors,management,careers,research pipeline,giapreza,grants,investor relations,corporate update,corporate presentation,recent news,prescribing information,wwwgiapreza com,close,scroll to top

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

La Jolla Pharmaceutical Company | | lajollapharmaceutical.com Reviews

https://lajollapharmaceutical.com

We are dedicated to the discovery, development, and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. La Jolla is developing LJPC-401 for the potential treatment of iron overload, which occurs as a result of hereditary hemochromatosis (HH), a genetic deficiency of hepcidin, or as a result of frequent blood transfusions required to treat diseases such as beta thalassemia and sickle cell disease (SCD).

INTERNAL PAGES

lajollapharmaceutical.com

1

La Jolla Pharmaceutical Company | LJPC-401

http://lajollapharmaceutical.com/product-pipeline/ljpc-401

LJPC-501 Market Opportunity Presentation. Latest News & Events. Corporate Governance & Nominating Committee Charter. LJPC-401 is La Jolla’s novel formulation of hepcidin. Hepcidin, an endogenous peptide hormone, is the body’s naturally occurring regulator of iron absorption and distribution. Hepcidin prevents excessive iron accumulation in vital organs, such as the liver and heart, where it can cause significant damage and even result in death. 2016 La Jolla Pharmaceutical Company.

2

La Jolla Pharmaceutical Company | La Jolla Pharmaceutical Company Announces Exclusive Worldwide License Agreements Covering LJPC-30Sa and LJPC-30Sb

http://lajollapharmaceutical.com/2015/08/la-jolla-pharmaceutical-company-announces-exclusive-worldwide-license-agreements-covering-ljpc-30sa-and-ljpc-30sb

LJPC-501 Market Opportunity Presentation. Latest News & Events. Corporate Governance & Nominating Committee Charter. La Jolla Pharmaceutical Company Announces Exclusive Worldwide License Agreements. La Jolla Pharmaceutical Company Announces Exclusive Worldwide License Agreements Covering LJPC-30Sa and LJPC-30Sb. August 5, 2015. Despite kidney toxicity, gentamicin has become one of the most commonly prescribed hospital antibiotics due to its broad spectrum of antimicrobial efficacy. Gentamicin consist...

3

La Jolla Pharmaceutical Company | Corporate Governance & Nominating Committee Charter

http://lajollapharmaceutical.com/investor-relations/corporate-governance/corporate-governance-nominating-committee-charter

LJPC-501 Market Opportunity Presentation. Latest News & Events. Corporate Governance & Nominating Committee Charter. Corporate Governance & Nominating Committee Charter. Corporate Governance & Nominating Committee Charter. The primary purpose of the Committee is to:. Identify individuals qualified to become directors;. Recommend directors for membership on Board committees; and. Review and recommend a set of corporate governance principles applicable to the Company. The following are the duties and respo...

4

La Jolla Pharmaceutical Company | Product Pipeline

http://lajollapharmaceutical.com/pages/product-pipeline

LJPC-501 Market Opportunity Presentation. Latest News & Events. Corporate Governance & Nominating Committee Charter. La Jolla’s drug development efforts are focused on several product candidates: LJPC-501. LJPC-401 has been shown to be effective in reducing serum iron in preclinical testing. La Jolla has initiated a Phase 1 clinical trial of LJPC-401 in patients at risk of iron overload due to conditions such as HH, beta thalassemia and SCD. 2016 La Jolla Pharmaceutical Company.

5

La Jolla Pharmaceutical Company | SEC Filings

http://lajollapharmaceutical.com/investor-relations/sec-filings

LJPC-501 Market Opportunity Presentation. Latest News & Events. Corporate Governance & Nominating Committee Charter. 8-K - Current report. Fri, Aug 26, 2016. 8-K - Current report. Fri, Aug 12, 2016. 10-Q - Quarterly report [Sections 13 or 15(d)]. Mon, Aug 08, 2016. DEF 14A - Other definitive proxy statements. Fri, Jul 22, 2016. 8-K - Current report. Wed, May 11, 2016. Latest News & Events. Corporate Governance & Nominating Committee Charter. 2016 La Jolla Pharmaceutical Company.

UPGRADE TO PREMIUM TO VIEW 15 MORE

TOTAL PAGES IN THIS WEBSITE

20

LINKS TO THIS WEBSITE

rtwfunds.com

RTW Investments

http://www.rtwfunds.com/careers.html

RTW invests with innovative health care companies looking to bring. Important new products to patients. Built on a foundation of deep research. RTW Investments is a healthcare-centered investment firm focused on the most innovative subsectors of healthcare. We believe in the value of deep scientific and commercial research. Assessing science can be hard and humbling, and so we have built a firm culture and structure to maximize the focus and patience it requires. The most broadly licensed AAV capsid tech...

rtwfunds.com

RTW Investments

http://www.rtwfunds.com/community.html

RTW invests with innovative health care companies looking to bring. Important new products to patients. Built on a foundation of deep research. RTW Investments is a healthcare-centered investment firm focused on the most innovative subsectors of healthcare. We believe in the value of deep scientific and commercial research. Assessing science can be hard and humbling, and so we have built a firm culture and structure to maximize the focus and patience it requires. The most broadly licensed AAV capsid tech...

rtwfunds.com

RTW Investments

http://www.rtwfunds.com/library.php

RTW invests with innovative health care companies looking to bring. Important new products to patients. Built on a foundation of deep research. RTW Investments is a healthcare-centered investment firm focused on the most innovative subsectors of healthcare. We believe in the value of deep scientific and commercial research. Assessing science can be hard and humbling, and so we have built a firm culture and structure to maximize the focus and patience it requires. The most broadly licensed AAV capsid tech...

commercialization.gwu.edu

Success Stories | Technology Commercialization Office | The George Washington University

https://commercialization.gwu.edu/success-stories

Skip to main content. Enter the terms you wish to search for. Virginia Science and Technology Campus. Online and Virginia Academic Centers. GWeb (Records and Registration). Division of Student Affairs. Colonial Central (Financial Services). GW Bulletin (Course Descriptions). Student Support and Family Engagement. Technology Innovation at GW: A Success Story. Akos Vertes, GW Chemistry Professor. The Technology Commercialization Office (TCO) licensed t he George Washington University (GW). For GW intellect...

UPGRADE TO PREMIUM TO VIEW 4 MORE

TOTAL LINKS TO THIS WEBSITE

8

OTHER SITES

lajollapetparade.com

掃除で運気をアップ

もったいないまだ使えるという物中心の考え方ではなく、生活の主役を自分へ移すもの。

lajollapets.com

The domain lajollapets.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.

lajollapetstores.com

The domain lajollapetstores.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.

lajollapetsupplies.com

The domain lajollapetsupplies.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.

lajollapettraining.com

The domain lajollapettraining.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.

lajollapharmaceutical.com

La Jolla Pharmaceutical Company |

We are dedicated to the discovery, development, and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. La Jolla is developing LJPC-401 for the potential treatment of iron overload, which occurs as a result of hereditary hemochromatosis (HH), a genetic deficiency of hepcidin, or as a result of frequent blood transfusions required to treat diseases such as beta thalassemia and sickle cell disease (SCD).

lajollapharmacies.com

The domain lajollapharmacies.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.

lajollapharmacy.com

The domain lajollapharmacy.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.

lajollaphotobooth.com

home

lajollaphotography.com

The domain lajollaphotography.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.

lajollaphysicaltherapists.com

The domain lajollaphysicaltherapists.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.